Lifecore Biomedical, Inc.
LFCR
$6.18
$0.030.49%
| 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | 11/26/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.01% | 0.75% | 21.64% | 34.55% | 37.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.01% | 0.75% | 21.64% | 34.55% | 37.90% |
| Cost of Revenue | 6.37% | -11.36% | -11.78% | 32.37% | 24.76% |
| Gross Profit | 11.32% | 97.47% | 122.03% | 39.14% | 75.33% |
| SG&A Expenses | 16.66% | 53.64% | -0.57% | -4.19% | 10.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.40% | 5.80% | -7.35% | 17.47% | 18.10% |
| Operating Income | -17.27% | -22.52% | 143.54% | 96.87% | 72.31% |
| Income Before Tax | -146.05% | -29.81% | 80.57% | 233.23% | 254.15% |
| Income Tax Expenses | 166.15% | -128.41% | -124.78% | 210.00% | -1,725.00% |
| Earnings from Continuing Operations | -146.14% | -28.71% | 80.85% | 230.49% | 254.79% |
| Earnings from Discontinued Operations | -- | -- | 100.13% | 103.36% | 99.33% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.22% | -50.92% | 81.97% | 142.82% | 211.03% |
| EBIT | -17.27% | -22.52% | 143.54% | 96.87% | 72.31% |
| EBITDA | 11.14% | -35.17% | 204.01% | 380.45% | 123.80% |
| EPS Basic | -154.26% | -48.71% | 82.21% | 142.56% | 208.03% |
| Normalized Basic EPS | -137.88% | -19.72% | 51.35% | 280.31% | 261.50% |
| EPS Diluted | -165.07% | -49.84% | 82.21% | 135.12% | 190.09% |
| Normalized Diluted EPS | -145.28% | -19.72% | 51.35% | 250.20% | 235.09% |
| Average Basic Shares Outstanding | 12.81% | 1.49% | 1.96% | 0.61% | 2.78% |
| Average Diluted Shares Outstanding | -5.65% | 1.49% | 1.96% | 20.81% | 22.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
